President Donald Trump has already begun targeting Joe Biden’s drug pricing policies, using an executive order to roll back a 2022 policy that set up new ways for Medicare and Medicaid to pay for expensive medications. The early focus is spooking some lawmakers about the future of Medicare price negotiations for one expensive and popular class of drugs in particular: GLP-1 inhibitors like Ozempic and Wegovy.
“We have made progress in negotiating prescription drug pricing through Medicare. It’s imperative that it be continued,” Sen. Bernie Sanders, the top Democrat on the Health, Education, Labor and Pensions Committee, told NOTUS.
“For years, Trump has campaigned on the reality that we pay by far the highest prices in the world for prescription drugs,” Sanders added. “At this point, at least, Trump is giving the message that he’s going to move in the wrong direction. It takes guts to stand up to Pharma. We will see whether Trump can do that.”